Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome

Conditions

Renal Insufficiency, Chronic

Keywords

Alport Syndrome, chronic kidney disease, renal fibrosis, nephroprotection, pediatric study

Brief summary

This is a phase III, multi-centre, randomised, placebo-controlled, patient and investigator-blind study in paediatric patients with early stages of Alport syndrome to assess the safety and efficacy of the ACEi ramipril in slowing disease progression. Alport syndrome stages that describe the extent of renal damage and loss of function are defined as: * 0 Microhaematuria without microalbuminuria (usually at birth) * I Microalbuminuria (30-300 mg albumin/gCrea) * II Proteinuria \>300 mg albumin/gCrea * III \> 25% decline of normal renal function (creatinine clearance) * IV End stage renal failure (ESRF) Eligible patients with Alport stages 0 and I will be randomly assigned at a 2:1 ratio to receive once daily ramipril or placebo. In addition, Alport stage II patients may be treated open Label. Eligible patients who, or whose parents/legal guardian refuse randomisation after eligibility is confirmed, and patients who have been treated with ramipril prior to the study, may be treated open-label with ramipril as per protocol. The total number of patients will not exceed 120, with the number of randomised patients not exceeding 60, and the number of patients treated open label from Day 1 of the study aimed to be approximately 60. Randomised patients whose disease progresses to the next disease level during the 3 year treatment period will be unblinded, and open label ramipril treatment will be initiated and continued, respectively, depending on prior treatment randomisation.

Gross O, Boeckhaus J, Weber LT, Heerspink HJL, Simon JF, Ahmed R, Gerst C, Duerr U, Walker F, Tostmann R, Helm J, Asendorf T, Friede T, study group of the German Society of Pediatric Nephrology .

2025-04-0115 citations

10.1093/ndt/gfae180

Ratio of Urinary Proteins to Albumin Excretion Shifts Substantially during Progression of the Podocytopathy Alport Syndrome, and Spot Urine Is a Reliable Method to Detect These Pathologic Changes

Jan Boeckhaus, Lea Mohr, Hassan Dihazi, Burkhard Tönshoff, Lutz T. Weber et al. (19 authors)

Cells2023-05-077 citations

10.3390/cells12091333

Challenges for academic investigator-initiated pediatric trials for rare diseases.

Ahmed R, Duerr U, Gavenis K, Hilgers R, Gross O.

2014-02-015 citations

10.1016/j.clinthera.2014.01.013

Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients.

Gross O, Friede T, Hilgers R, Görlitz A, Gavénis K, Ahmed R, Dürr U.

2012-07-0150 citations

10.5402/2012/436046

Interventions

DRUGRamipril

Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.

DRUGplacebo to ramipril

Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

24 Months to 18 Years

Healthy volunteers

No

Inclusion criteria

* Definitive diagnosis of Alport syndrome: Kidney biopsy (patient or affected relative/s), and/or mutation analysis (hemizygous X-chromosomal or homozygous autosomal-recessive) and assessment of criteria for clinical diagnosis (haematuria, positive family history regarding kidney diseases, ocular changes, labyrinthine hearing loss) * Alport syndrome levels 0, I or II at screening (microhaematuria without microalbuminuria or microalbuminuria \[30-300 mg albumin/gCrea\]) or proteinuria \>300 mg albumin/gCrea with GFR\>80ml/min). Patients with Alport stage II are not subject to randomization but are treated opel label. * Aged between ≥24 months and \<18 years at screening * Assent from patient and informed consent from parents/legal guardian

Exclusion criteria

* Uncertain diagnosis or variants of Alport syndrome such as a heterozygous carrier * Alport syndrome levels III, or IV (albuminuria \>300 mg/g Crea, creatinine clearance \<60 mL/min, or end stage renal failure \[ESRF\]) * Known allergies or intolerances to ramipril or related compounds * Known contraindication for ACEi-therapy * Additional chronic renal, pulmonary or cardiac diseases * Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame	Description
Time to next disease level	within 3 years	Time to progression of Alport Syndrome to the next disease level within 3 years under ramipril treatment compared to placebo, for all randomised patients.
Incidence of Adverse Drug Events before progression	within 3 years	Incidence of adverse drug events (ADEs, e.g., angioedema, acute renal failure, hyperkalaemia) under ramipril treatment before disease progression compared to placebo before disease progression, for all randomised patients.

Secondary

Measure	Time frame	Description
Albuminuria after three years	after 3 years	Albuminuria after 3 years corrected for baseline albuminuria for patients randomised to receive ramipril compared to placebo.
Adverse Drug Events over three years	after 3 years	Incidence of ADEs (e.g., angioedema, acute renal failure, hyperkalaemia) during 3 years of treatment for patients randomised to receive ramipril compared to placebo.

Countries

Germany

Outcome results

None listed